PNV belongs to the Health Care sector. Filings by its managers are published through ASX. Between 18 October 2025 and 18 October 2026, 3 insiders published 8 filings.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 2,530 companies tracked on its exchange, the median is 3 filings; at 8 filings, this issuer sits above that mark.
Over the last twelve months, not one insider purchase of PNV stock was filed.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Analysts rate PNV Buy (bullish), based on 7 analysts. Average price target: A$1.25.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
8 of 8 declarations
PNV is a company operating in the healthcare and pharmaceutical sector, listed on the XASX market. It focuses on developing innovative solutions to enhance healthcare.
Purchases our model currently ranks for the recommendations list.
All recommendations